Interpretable machine learning in predicting drug-induced liver injury among tuberculosis patients: model development and validation study

被引:4
|
作者
Xiao, Yue [1 ]
Chen, Yanfei [1 ]
Huang, Ruijian [1 ]
Jiang, Feng [1 ]
Zhou, Jifang [1 ]
Yang, Tianchi [2 ]
机构
[1] China Pharmaceut Univ, Sch Int Pharmaceut Business, Nanjing, Jiangsu, Peoples R China
[2] Ningbo Municipal Ctr Dis Control & Prevent, Inst TB Prevent & Control, 237 Yongfeng Rd, Ningbo, Zhejiang, Peoples R China
关键词
Machine learning; Logistic regression; Tuberculosis; Drug-induced liver injury; Retrospective study; HEALTH; HEPATOTOXICITY; GUIDELINES;
D O I
10.1186/s12874-024-02214-5
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background The objective of this research was to create and validate an interpretable prediction model for drug-induced liver injury (DILI) during tuberculosis (TB) treatment.Methods A dataset of TB patients from Ningbo City was used to develop models employing the eXtreme Gradient Boosting (XGBoost), random forest (RF), and the least absolute shrinkage and selection operator (LASSO) logistic algorithms. The model's performance was evaluated through various metrics, including the area under the receiver operating characteristic curve (AUROC) and the area under the precision recall curve (AUPR) alongside the decision curve. The Shapley Additive exPlanations (SHAP) method was used to interpret the variable contributions of the superior model.Results A total of 7,071 TB patients were identified from the regional healthcare dataset. The study cohort consisted of individuals with a median age of 47 years, 68.0% of whom were male, and 16.3% developed DILI. We utilized part of the high dimensional propensity score (HDPS) method to identify relevant variables and obtained a total of 424 variables. From these, 37 variables were selected for inclusion in a logistic model using LASSO. The dataset was then split into training and validation sets according to a 7:3 ratio. In the validation dataset, the XGBoost model displayed improved overall performance, with an AUROC of 0.89, an AUPR of 0.75, an F1 score of 0.57, and a Brier score of 0.07. Both SHAP analysis and XGBoost model highlighted the contribution of baseline liver-related ailments such as DILI, drug-induced hepatitis (DIH), and fatty liver disease (FLD). Age, alanine transaminase (ALT), and total bilirubin (Tbil) were also linked to DILI status.Conclusion XGBoost demonstrates improved predictive performance compared to RF and LASSO logistic in this study. Moreover, the introduction of the SHAP method enhances the clinical understanding and potential application of the model. For further research, external validation and more detailed feature integration are necessary.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Prevention of drug-induced liver injury in patients with pulmonary tuberculosis and chronic hepatitis C
    Ivanova, Diana
    Borisov, Sergey
    Kudlay, Dmitriy
    Nikolenko, Nicolay
    Slogotskaya, Ludmila
    Garmash, Yulia
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [42] Drug-Induced Liver Injury: Biomarkers, Requirements, Candidates, and Validation
    Meunier, Lucy
    Larrey, Dominique
    FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [43] Artificial Intelligence and Machine Learning Models for Predicting Drug-Induced Kidney Injury in Small Molecules
    Rao, Mohan
    Nassiri, Vahid
    Srivastava, Sanjay
    Yang, Amy
    Brar, Satjit
    Mcduffie, Eric
    Sachs, Clifford
    PHARMACEUTICALS, 2024, 17 (11)
  • [44] A nomogram model to predict the risk of drug-induced liver injury in patients receiving anti-tuberculosis treatment
    Ji, Songjun
    Lu, Bin
    Pan, Xinling
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [45] Exploring Variability in Rifampicin Plasma Exposure and Development of Anti-Tuberculosis Drug-Induced Liver Injury among Patients with Pulmonary Tuberculosis from the Pharmacogenetic Perspective
    Kivrane, Agnija
    Ulanova, Viktorija
    Grinberga, Solveiga
    Sevostjanovs, Eduards
    Viksna, Anda
    Ozere, Iveta
    Bogdanova, Ineta
    Zolovs, Maksims
    Ranka, Renate
    PHARMACEUTICS, 2024, 16 (03)
  • [46] Development and validation of an interpretable machine learning model for predicting the risk of hepatocellular carcinoma in patients with chronic hepatitis B: a case-control study
    Wu, Linghong
    Liu, Zengjing
    Huang, Hongyuan
    Pan, Dongmei
    Fu, Cuiping
    Lu, Yao
    Zhou, Min
    Huang, Kaiyong
    Huang, Tianren
    Yang, Li
    BMC GASTROENTEROLOGY, 2025, 25 (01)
  • [47] The Frequency of Drug-Induced Liver Injury Due to Antibiotics Among Hospitalised Patients
    Bjornsson, Robert A.
    Sigurdsson, Sigurdur Solvi
    Arnarson, Dagur Tjorvi
    Logason, Egill
    Bjornsson, Einar Stefan
    DRUG SAFETY, 2025,
  • [48] Development of an Australian drug-induced liver injury network
    Rodrigues, B.
    Chauhan, A.
    Bishara, M.
    Haar, G.
    Nicoll, A. J.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 45 - 46
  • [49] Drug-Induced Liver Injury: A Clinicopathologic Study of 380 Chinese Patients
    Zhang, Ting
    Teng, Xiao-Ying
    Wang, Peng
    Wang, Yan-Bin
    Yan, Jie
    Zhao, Hong
    HuangFu, Jing-Kun
    Wang, Jing-Jing
    Fan, Ying
    Cheng, Cheng
    Cheng, Jun
    Wang, Hanlin L.
    Xie, Wen
    GASTROENTEROLOGY, 2014, 146 (05) : S1001 - S1001
  • [50] The development of a hepatic steatotic model for assessment of drug-induced liver injury susceptibility
    Regan, Sophie
    Srivastava, Abhi
    Foster, Alison
    Rollison, Helen
    Williams, Dominic
    TOXICOLOGY LETTERS, 2017, 280 : S134 - S134